A recent report showed that CIP2A could protect the hepatocellular carcinoma (HCC) cell lines from bortezomib-induced apoptosis by inhibiting phosphor-AKT-associated PP2A phosphatase activity (18). Here, PTPA is linked to hepatocellular carcinoma.